National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 27 of 41
9-valent CRM 197 Pneumococcal
NCT00133549
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
NCT00008463
Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease
NCT00006417
A Study of HIV-Disease Development in Aging
NCT00006144
Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women
NCT00006320
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
NCT00031486
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
NCT00006145
Half-Dose Flu Vaccine Study in Healthy Adults
NCT00006146
Immune Function of Infants With HIV
NCT00073229
Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus
NCT00005924
Genetic Factors in Atherosclerosis
NCT00359307
The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children
NCT00006064
Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers
NCT00005907
Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders
NCT00005933
Azithromycin/Bicillin Syphilis
NCT00031499
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
NCT00005673
Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy
NCT00009256
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
NCT00007787
Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections
NCT00004996
Network on Antimicrobial Resistance in Staphylococcus Aureus
NCT00341913
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
NCT00004978
A Test of Behavioral Intervention for Women at High Risk for HIV Infection
NCT00006440
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
NCT00004567
The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV
NCT00004735
Once-Daily Drug Regimen for HIV-Infected Patients
NCT00001968
Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection
NCT00001976
Intermittent Versus Continuous Medication in the Treatment of HIV
NCT00001967
Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination
NCT00001132
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
NCT00000936
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
NCT00001119
Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients
NCT00069498
The Biology of HIV Transmission
NCT00001092
Outcomes of Anti-HIV Therapy During Early HIV Infection
NCT00001093
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
NCT00001145
A Study to Monitor Patients With Primary or Early HIV Infection
NCT00000911
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
NCT00342589
Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
NCT00001912
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth
NCT00031447
A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1
NCT00001121
Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients
NCT00001110
Mechanisms of Allergen Immunotherapy
NCT00001910
Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections
NCT00001911
Treatment of Acute HIV Infection to Preserve Immune Function
NCT00055094
T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma
NCT00001908
Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
NCT00001909
A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss
NCT00000925
Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV
NCT00000940
Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants
NCT00001906
Prevention of RSV Infections in Bone Marrow Transplant Recipients
NCT00001903
Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I
NCT00001905
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.